Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
CNY 61.86
(1.51%)
CNY 61.86
(1.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 284.49 Million CNY | -46.2% |
| 2022 | 528.8 Million CNY | -28.03% |
| 2021 | 734.7 Million CNY | 311.73% |
| 2020 | 178.44 Million CNY | 354.04% |
| 2019 | 39.3 Million CNY | -0.42% |
| 2018 | 39.46 Million CNY | -24.05% |
| 2017 | 51.96 Million CNY | 60.31% |
| 2016 | 32.41 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 280.73 Million CNY | -24.17% |
| 2024 Q1 | 298.05 Million CNY | 4.76% |
| 2024 Q2 | 370.2 Million CNY | 24.21% |
| 2023 Q3 | 294.79 Million CNY | -1.48% |
| 2023 FY | 284.49 Million CNY | -46.2% |
| 2023 Q4 | 284.49 Million CNY | -3.49% |
| 2023 Q2 | 299.23 Million CNY | -14.63% |
| 2023 Q1 | 350.49 Million CNY | -33.72% |
| 2022 FY | 528.8 Million CNY | -28.03% |
| 2022 Q3 | 365.72 Million CNY | -19.04% |
| 2022 Q4 | 528.8 Million CNY | 44.59% |
| 2022 Q2 | 451.76 Million CNY | -42.21% |
| 2022 Q1 | 781.72 Million CNY | 6.4% |
| 2021 Q2 | 175.05 Million CNY | -29.16% |
| 2021 FY | 734.7 Million CNY | 311.73% |
| 2021 Q1 | 247.09 Million CNY | 38.47% |
| 2021 Q4 | 734.7 Million CNY | 228.75% |
| 2021 Q3 | 223.48 Million CNY | 27.67% |
| 2020 Q3 | 61.22 Million CNY | -56.97% |
| 2020 Q2 | 142.27 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 178.44 Million CNY | 354.04% |
| 2020 Q4 | 178.44 Million CNY | 191.47% |
| 2019 Q4 | 39.3 Million CNY | 0.0% |
| 2019 FY | 39.3 Million CNY | -0.42% |
| 2018 FY | 39.46 Million CNY | -24.05% |
| 2017 FY | 51.96 Million CNY | 60.31% |
| 2016 FY | 32.41 Million CNY | 0.0% |